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Edited by Sandro SonninoAbstract We have previously described a bacterial system for
the conversion of globotriaose (Gb3) into globotetraose (Gb4)
by a metabolically engineered Escherichia coli strain expressing
the Haemophilus inﬂuenzae lgtD gene encoding b1,3-N-acety-
lgalactosaminyltransferase [Antoine, T., Bosso, C., Heyraud,
A. Samain, E. (2005) Large scale in vivo synthesis of globotriose
and globotetraose by high cell density culture of metabolically
engineered Escherichia coli. Biochimie 87, 197–203]. Here, we
found that LgtD has an additional b1,3-galactosyltransferase
activity which allows our bacterial system to be extended to
the synthesis of the carbohydrate portion of globopentaosylcera-
mide (Galb-3GalNAcb-3Gala-4Galb-4Glc) which reacts with the
monoclonal antibody deﬁning the stage-speciﬁc embryonic anti-
gen-3. In vitro assays conﬁrmed that LgtD had both b1,3-GalT
and b1,3-GalNAcT activities and showed that diﬀerences in the
aﬃnity for Gb3 and Gb4 explain the speciﬁc and exclusive for-
mation of globopentaose.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The globopentaose Gb5 (Galb-3GalNAcb-3Gala-4Galb-
4Glc) is the carbohydrate moiety of the globopentaosylcera-
mide [2] which has been ﬁrst identiﬁed in tetracarcinoma cells
as a structure reacting with the monoclonal antibody MC631Abbreviations: SSEA-3, stage-speciﬁc embryonic antigen-3; Gb5,
globopentaose; Gb4, globotetraose; Gb3, globotriaose; GT, glycosyl-
transferase; GalT, galactosyltransferase; GalNAcT, N-acetylgalactos-
aminyltransferase; PCR, polymerase chain reaction; IPTG, isopropyl
1-thio-b-galactopyranoside; TLC, thin layer chromatography; UDP-
Gal, uridine diphosphate-galactose; UDP-GlcNAc, uridine diphos-
phate-N-acetylglucosamine; UDP-GalNAc, uridine diphosphate-N-
acetylgalactosamine; TFA, triﬂuroacetic acid; HPAEC, high pH anion
exchange chromatography; GC–MS, gas chromatography–mass spec-
trometry; ESI-MS, electrospray ionization mass spectrometry; NMR,
nuclear magnetic resonance
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doi:10.1016/j.febslet.2007.05.008that deﬁnes the stage-speciﬁc embryonic antigen-3 (SSEA-3)
and whose epitope is R-GalNAcb-3Gala-4Gal. The pentasac-
charide sequence is also found in other related glycolipids of
the globo-series reacting with the monoclonal anti-SSEA-3.
They carry an additional fucose (Globo-H) [3] or sialic acid
(SSEA-4 antigen) [2] on the terminal galactosyl residue of
Gb5. These embryonic epitopes have been identiﬁed on vari-
ous tumor cells [4] and are promising targets for the develop-
ment of anti-cancer vaccines [5].
Chemical synthesis of Gb5 was ﬁrst achieved in 1988 [6] but
the high potential interest of this molecule and of its possible
derivatives for cancer immunotherapy has led several groups
to investigate diﬀerent strategies to improve the synthetic
yields [7–9].
An alternative to these very demanding chemical syntheses is
the enzymatic approach which has been successfully applied to
the synthesis of globotriaose (Gb3) [10] and globotetraose
(Gb4) [11] using Neisseria meningitidis a1,4-galactosyltransfer-
ase (LgtC) and b1,3-N-acetylgalactosaminyltransferase from
Haemophilus inﬂuenzae strain Rd (LgtD) [12]. In addition,
large-scale enzymatic synthesis of oligosaccharides can be con-
veniently achieved in whole bacterial cells [13] and we have re-
cently designed a bacterial system for the production of Gb4
by taking advantage of the fact that living Escherichia coli cells
can actively internalize Gb3 [1]. As shown in Fig. 1, this system
could be extended to the synthesis of Gb5 if the suitable b1,3-
galactosyltransferase could be found. Up to now the only
enzyme reported to direct the synthesis of the globopentaosyl-
ceramide has been the human b1,3-galactosyltransferase V
[14]. However, the use of this enzyme for the production of
Gb5 in metabolically engineered E. coli cells could be seriously
hampered by the fact that mammalian glycosyltransferase
genes are generally badly expressed in bacteria. Another
b1,3-galactosyltransferase candidate is the CgtB protein from
Campylobacter jejuni, which add a galactosyl residue on a N-
acetylgalactosaminyl b1,4-linked motif [15]. The initial goal
of this study was thus to investigate the production of Gb5
by an E. coli strain coexpressing lgtD and one of these above
mentioned b1,3-galactosyltransferase genes. However, in the
course of these investigations, we surprisingly found that
E. coli cells expressing lgtD alone converted Gb4, which was
produced from Gb3, into Gb5. We now present evidence that
the LgtD protein from H. inﬂuenzae, which normally acts as a
b1,3-N-acetylgalactosaminyltransferase in presence of Gb3,
has an additional b1,3-galactosyltransferase activity in pres-
ence of Gb4 as the acceptor.blished by Elsevier B.V. All rights reserved.
Fig. 1. Metabolically engineered pathway for globopentaose (Gb5)
production from exogenous globotriaose (Gb3) in Escherichia coli K
12. Gb3 is internalized by the b-galactoside permease LacY and cannot
be degraded because the DM strain is a lacZ melA mutant devoid of a-
and b-galactosidase activities. The expression of Pseudomonas aeru-
ginosa wbpP or Campylobacter jejuni gne enables the epimerization of
UDP-GlcNAc into UDP-GalNAc. The Gb3 acceptor is converted into
Gb4 by b1,3-GalNAcT encoded by Haemophilus inﬂuenzae LgtD. The
subsequent conversion of Gb4 into Gb5 requires the expression of
b1,3-GalT.
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2.1. Bacterial strains, plasmids and cloning procedures
To construct the pBS-lgtD plasmid, the H. inﬂuenzae lgtD gene was
subcloned from pBluescript-lgtDC [1] into the SalI–PstI sites of pBlue-
script II KS. The C. jejuni gne gene was ampliﬁed by polymerase chain
reaction (PCR) from the genomic DNA of the NCTC 11168 strain
using the following primers 5 0-AGGAGGATTATTGATGAAA-
ATTCTTATTAGCGGTG and 5 0-AGAGCTCGCCAAAGTGATA-
AAAGGCATTA. The PCR product was cloned into pCR4Blunt-
TOPO and subcloned into the XhoI–EcoRI sites of the pBBR1-
MCS3 vector [16] to yield pBBR-gne and into the PstI–SacI sites of
pBS-lgtD to yield pBS-lgtD-gne.
The DM strain was constructed from the DC strain [17] by inactivat-
ing the melA gene encoding a-galactosidase activity as previously de-
scribed in [18]. MR13, MR14 and MR15 strains were obtained by
transforming the DC strain with the plasmids pBS-lgtD, pBBR-gne
and pBS-lgtD-gne, respectively.
2.2. Production of oligosaccharides in high cell density culture
High cell density cultures were carried out at 34 C and pH 6.8 in 2-
liter reactors containing mineral culture medium (1 l) as previously de-
scribed [19]. They consisted of three phases: an exponential-growth
phase, which started with inoculation of the fermenter and lasted until
exhaustion of the initially added glycerol (17.5 g/l), a 5 h fed-batch
phase with a high substrate-feeding rate (4.5 g/l/h) and a 19 h fed-batch
phase with a lower feeding rate (2.4 g/l/h). The acceptor (Gb3, 3 g/l)
and the inducer (IPTG, 50 mg) were added at the end of the exponen-
tial phase. Culture samples were prepared and analyzed by thin layer
chromatography (TLC) as previously described [1].
2.3. Assay for b1,3-GalNAcT and b1,3-GalT activities
For protein expression, cell extracts of DM, MR13 and MR14
strains were prepared as previously described [20]. The enzymatic as-
says were performed at 30 C for 2 h in a ﬁnal volume (100 ll) contain-
ing 50 mM Tris–HCl (pH 7.0), 10 mM MnCl2, l% BSA, 3 mM
acceptor (Gb3 or Gb4) and 10 ll of protein extract from DM andMR13 strains. For the b1,3-GalT assay, 0.3 mM uridine diphos-
phate-galactose (UDP-Gal) and 1.68 lM 14C-UDP-Gal (Amersham,
2.5 lCi) were used as donors while 0.3 mM uridine diphosphate-
N-acetylglucosamine (UDP-GlcNAc) and 2.12 lM 14C-UDP-GlcNAc
(Amersham, 10 lCi) were used as donors for the b1,3-GalNAcT assay.
In the latter assay, the mixture was incubated at 30 C for 1 h with pro-
tein extract from the MR14 strain to provide uridine diphosphate-
N-acetylgalactosamine (UDP-GalNAc) before adding the MR13
strain. Reactions were stopped by adding Dowex 1 · 8-400 chloride
anion-exchange resin (500 ll, 0.25 g/ml in water). After centrifugation,
the supernatant was added to liquid scintillation cocktail (4 ml, Amer-
sham) to quantify the incorporated radioactivity.
2.4. Puriﬁcation of oligosaccharides
At the end of the fermentation period, bacterial cells were recovered
by centrifugation (7000·g, 30 min), and the supernatant was desig-
nated the extracellular fraction. The cells contained in the pellet were
resuspended in water, and permeabilized by autoclaving at 100 C
for 50 min. After an additional identical centrifugation, the intracellu-
lar oligosaccharides were found in the supernatant. They were ad-
sorbed on activated charcoal/celite (1:1) and eluted with 50%
aqueous ethanol. Finally, they were separated by size-exclusion chro-
matography on a Biogel P2 column (200 · 1.5 cm) at 60 C, with water
as the mobile phase and at a ﬂow rate of 35 ml/h.
2.5. Carbohydrate structural analysis
Glycosyl composition analysis. Three milligrams of pentasaccharide
were hydrolyzed in 500 ll, 2 M triﬂuoroacetic acid (TFA) containing
m-inositol (0.964 mg/ml) at 100C for 4 h. TFA was removed by re-
peated evaporations with distilled water to obtain a neutral pH. The
resulting sample was analyzed by high pH anion exchange chromatog-
raphy (HPAEC) with pulsed amperometric detection (PAD) on a Dio-
nex CarboPac PA-10 column (250 · 4 mm) [21].
Alditol acetates of the monosaccharides were obtained after reduc-
tion (NaBH4 at 37  for 4 h) and acetylation (acetic anhydride/pyridine
(1/1, v:v) at room temperature for 20 h). They were analyzed on a HP
5890 gas chromatograph (Hewlett–Packard, France) ﬁtted with a
ﬂame-ionization detector with a SP-2380 column (30 m · 0.53 mm),
using He as the carrier gas.
GC–MS.Reduced pentasaccharide (3 mg) was dissolved in dimethyl-
sulfoxide (200 ll), methylsulﬁnyl carbanion (200 ll) was added and the
mixture was ﬂushed with N2 overnight. Methyl iodide (200 ll) was
added gradually. The methylated sample was extracted three times with
chloroform, washed with distilled water and dried with Na2SO4. After
evaporation, 500 ll of 90% formic acid was added and heated under re-
ﬂux for 1 h. A second hydrolysis was performed with 2 M TFA at
100 C for 2 h. After evaporation, the resulting monosaccharides were
reduced with NaBD4 and acetylated. The resulting partially methylated
alditol acetates were analyzed by GC–MS as previously described [22].
Electrospray ionization mass spectrometry (ESI-MS) and nuclear
magnetic resonance (NMR). ESI mass spectra were recorded on a
ZQ Waters micromass spectrometer (capillary 3.5 kV, cone voltage
80 V). 1H and 13C NMR spectra were performed with a 300 MHz Bru-
ker AVANCE spectrometer.
Gb5: ESI-MS: m/z 892 [M+Na+]; 1H NMR (D2O, 303 and 323 K):
d = 5.23 (H-1a, d, J = 3.4 Hz, 1H), 4.93 (H-100, d, J = 2.7 Hz, 1H),
4.72 (H-1000, d, J = 7.15 Hz, 1H), 4.66 (H-1b, d, J = 10 Hz, 1H), 4.52
(H-1 0, d, J = 7.5 Hz, 1H), 4.46 (H-10000, d, J = 7.6 Hz, 1H), 4.38(H-500,
t, J = 6.4 Hz, 1H), 4.26 (H-400, d, J = 4.2 Hz, 1H), 4.18 (H-4000, s, 1H),
3.64 (H-2b, t, J = 8 Hz, 0.6H), 2.04 (Ac, s, 3H); 13C NMR (D2O) :
d = 175.78 (CO), 105.6 (C-10000), 104.12 (C-1 0), 103.76 (C-1000),
101.29 (C-100), 96.61 (C-1b), 92.68 (C-1a), 80.44 (C-3000), 79.74 (C-300),
61.89 - 60.9 (all C-6), 52.41 (C-2000), 23.22 (CH3).3. Results
3.1. Globopentaose production by metabolically engineered
E. coli cells
In our previously published system for Gb4 production with
the TA21 strain [1], the lgtD and wbpP genes were placed on
two separate plasmids, pACT3-lgtD and pBBR-wbpP. In order
2654 M. Randriantsoa et al. / FEBS Letters 581 (2007) 2652–2656to reduce the number of plasmids and to optimize Gb4 pro-
duction, the wbpP gene was replaced by the C. jejuni gne gene,
which has been shown to encode a more active UDP-GlcNAc
C4-epimerase, and both gne and lgtD genes were cloned to-
gether on the high copy number pBluescript plasmid to yield
pBS-lgtD-gne. Prior to investigating the production of Gb5
by expressing an additional gene for b1,3-galactosyltransfer-
ase, the control MR15 strain carrying the pBS-lgtD-gne plas-
mid was examined for Gb4 production. TLC analysis of the
intracellular oligosaccharide content of the MR15 strain indi-
cated that Gb4 production rates were signiﬁcantly improved
when compared with the results of the TA21 strain. Gb3
(3 g/l) was entirely converted into Gb4 within 4 h of incubation
with the MR15 strain, whereas it took 6 h for the TA21 strain
to convert only 1 g/l. TLC analysis of the intracellular fraction
of the MR15 strain (Fig. 2) also clearly revealed the presence
of an unidentiﬁed compound which started to be formed after
the complete exhaustion of Gb3 (4 h). After 20 h of incuba-
tion, Gb4 had almost entirely disappeared and the unidentiﬁed
compound had become the major detectable product. Its full
characterization showed that it was Gb5 (see Section 3.2). A
mixture of oligosaccharides (2.7 g) was isolated from the cell
medium and puriﬁcation on a Biogel P2 column showed that
it was composed of a mixture of Gb5, Gb4 and Gb3 in a ratio
of 85/5/10.
3.2. Characterization
At the end of the MR15 strain fermentation, the major prod-
uct was ﬁrst characterized by ESI mass spectrometry. Its ESI+
mass spectrum showed the presence of a quasi molecular ion
[M+Na]+ at m/z 892, which could have originated from a pen-
tasaccharide having 4 hexoses and one N-acetylhexosaminyl
residue. The determination of the monomeric sugar composi-
tion by HPAEC-PAD analysis after acid hydrolysis indicated
that this pentasaccharide was composed of Glc, Gal and Gal-
NAc monomers in a ratio of 1/3/1. This strongly suggested that
the pentasaccharide was formed by the transfer of one galacto-
syl unit onto a molecule of Gb4. The linkage position of the
additional galactose was determined by gas chromatogra-
phy–mass spectrometry (GC–MS) analysis after methylation,
acid-hydrolysis, reduction and acetylation of the pentasaccha-
ride. The presence of fragment ions at m/z 261 and 161 derived
from the N-acetylgalactosaminyl residue unambiguously dem-Fig. 2. TLC plate analysis of the oligosaccharide content in extracel-
lular (lanes 2–6) and intracellular (lanes 8–12) fractions of samples
withdrawn from the culture of the globopentaose-producing MR15
strain. Standards are in lane 1 (lactose, lacto-N-neotetraose, lacto-N-
neohexaose) and lane 7 (Gb4 and Gb5).onstrated that the linkage was at the third position. Compared
with the 13C NMR spectrum of Gb4, the spectrum of the pen-
tasaccharide showed an additional signal at 105.6 ppm indicat-
ing that the third galactosyl residue was attached to the
GalNAc unit with a b linkage. These results showed that the
pentasaccharide produced by the MR15 strain from Gb3 has
the structure of Gb5. This identiﬁcation was conﬁrmed by
the overall 1H and 13C NMR data that agreed closely with val-
ues previously published for 3-aminopropyl galactosylglobo-
side [23].
3.3. Speciﬁcity of LgtD
Enzymatic assays showed that crude extracts from the
MR13 strain expressing the LgtD protein had both b1,3-
GalNAcT and b1,3-GalT activities in the presence of Gb3 or
Gb4 as acceptors (Table 1). Control experiments with extracts
from the DM strain showed no detectable activity indicating
that both glycosyltransferase activities resulted from the
expression of LgtD. The maximum velocities of the two glyco-
syltransferases (GT) were in the same range regardless of the
acceptor and sugar donor used. However large diﬀerences in
the aﬃnity of the enzyme for UDP-Gal or UDP-GalNAc were
observed as a function of the acceptor used. When Gb3 was
the acceptor, the Km was 6 times lower for UDP-GalNAc than
for UDP-Gal, indicating that LgtD acted primarily as a Gal-
NAc-transferase, converting Gb3 into Gb4. When Gb3 was re-
placed by Gb4 as the acceptor, there was a 20-fold increase in
the Km for UDP-GalNAc but, on the other hand, in a 3.5-fold
decrease in the Km for UDP-Gal. In the presence of Gb4 as the
acceptor, the enzyme, which had an 11-fold greater aﬃnity for
UDP-Gal than for UDP-GalNAc, can thus be regarded as a
galactosyltransferase which speciﬁcally directs the synthesis
of Gb5.
3.4. Sequence analysis
The lgtD gene encodes a polypeptide of 323 aminoacids.
Protein sequence analysis revealed the presence of the N-termi-
nal domain which comprises residues [1–240] corresponding to
the catalytic domain. It shows a strong level of sequence sim-
ilarity (60–70% identity) to a number of bacterial GTs involved
in lipopolysaccharide biosynthesis, which belong to the large
CAZY GT2 family (http://afmb.cnrs-mrs.fr/CAZY/). This do-
main is assumed to adopt the mixed a/b GT-A fold ﬁrst ob-
served in the inverting GT SpsA [24]. An Aˆ00Asp-X-AspAˆ00
motif (where X is any amino acid) implicated in divalent metal
ion binding is formed by Asp92 and Asp94. The size of the cat-
alytic domain is indicative of a classical monofunctional en-
zyme belonging to the GT-A family and only one catalytic
center is clearly identiﬁed using fold recognition methods
[25]. Therefore the dual enzyme activity (b1,3-GalT/b1,3-Table 1
Kinetic parameters for the b1,3-GalNAcT and b1,3-GalT activities of
LgtD
Donornacceptor Globotriaose (Gb3) Globotetraose (Gb4)
Km
a Vmax
(pmol/min)
Km
a Vmax
(pmol/min)
UDP-GalNAc 0.81 21.27 16.66 10.00
UDP-Gal 5.00 15.15 1.42 16.60
aKm (mM) is the Michaelis–Menten constant for the Gb3 and Gb4
acceptors with concentrations covering the range 0.5–20 mM.
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sugar speciﬁcity that appears to be dictated by the acceptor
molecule. In contrast, the C-terminal region which comprises
residues [21–323] does not match any known GT catalytic do-
main. It is only observed in a small subset of closely related
LgtD protein sequences and is predicted to adopt an a-helical
fold. It is currently not known if this region is required for
the catalytic activity of LgtD but it can be suggested that
this C-terminal region may be involved in protein oligomeriza-
tion as was recently proposed for a mannosylglycerate syn-
thase that also displayed an extra C-terminal a-helical
domain [26].4. Discussion
There is no endogenous b1,3-galactosyltransferase in E. coli
and the formation of Gb5 using the MR15 strain expressing
the lgtD gene clearly results from a galactosyltransferase activ-
ity of the LgtD protein. It is not surprising that LgtD could act
as a galactosyltransferase because it has already been shown
that this enzyme can use UDP-Gal with a low eﬃciency with
Gb3 as the acceptor [27]. In addition, there are several reports
of GalNAc-transferases that have a side galactosyltransferase
activity [28] and the blood groups A and B glycosyltransferases
are known to diﬀer only by a few amino acids [29]. What is
quite remarkable in Gb5 production by the MR15 strain is
the fact that LgtD speciﬁcally adds a galactosyl residue onto
Gb4 but does not galactosylate Gb3 to produce the globotet-
raose analog Galb-3Gala-4Galb-4Glc. It is also notable that
LgtD does not produce the globopentaose analog GalNAcb-
3GalNAcb-3Gala-4Galb-4Glc from Gb4 in vivo. This very
high speciﬁcity could be explained by the presence of two sep-
arate active sites, as was demonstrated in other GTs such as
hyaluronan synthase [30] and chondroitin synthase [31] which
catalyze the successive transfer of two distinct sugars. How-
ever, LgtD is a relatively small protein of only 323 aminoacids
and its sequence analysis reveals only one putative catalytic
site. The presence of only one active site is also consistent with
the in vitro assay results which showed that the two activities
were observed with both Gb3 and Gb4 as acceptors. The
explanation for the unusual speciﬁcity of LgtD probably lies
in the diﬀerence in aﬃnity for UDP-GalNAc and UDP-Gal
that was observed as a function of the acceptor. In the presence
of Gb3, LgtD acts as a N-acetylgalactosaminyltransferase be-
cause it has a high aﬃnity for UDP-GalNAc and a low aﬃnity
for UDP-Gal. Conversely in the presence of Gb4, LgtD acts as
a galactosyltransferase because it has a higher aﬃnity for
UDP-Gal than for UDP-GalNAc. In this hypothesis, the
mechanism by which the acceptor can modulate the aﬃnity
for the sugar donor remains to be established.
An important question raised by these results is whether the
double speciﬁcity of LgtD is fortuitous or has a real physiolog-
ical signiﬁcance. LgtD is involved in the synthesis of the Gb4
epitope in the lipopolysaccharide of H. inﬂuenzae [32]. The
expression of the globoside mimics is believed to contribute
to pathogenicity by allowing the bacteria to evade the host im-
mune response. In this respect it could be interesting to deter-
mine if Gb5 is expressed on the H. inﬂuenzae cell surface as a
result of the galactosyltransferase activity of LgtD.
Regardless of its biological meaning, the b1,3-galactosyl-
transferase activity of LgtD is of great biotechnological impor-tance and LgtD is the ﬁrst reported enzyme that can be used
for the practical enzymatic synthesis of Gb5. Furthermore
the expression of LgtD in the metabolically engineered
E. coli strain is a very eﬃcient method to produce large quan-
tities of Gb5. Since we have shown that it is possible to synthe-
size fucosyl a1,2-linked [20] and sialyl a2,3-linked
oligosaccharides [33] in E. coli, it should certainly be possible
in the future to extend the method to the production of Glo-
bo-H and SSEA-4 antigens.
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